Mike Evers, Author at ORTHOWORLD

Enovis CEO Talks Tech, ASCs and Strategic Focus

We spoke to Enovis CEO Matt Trerotola about foundational implant technologies, ASC penetration, tech adoption and successful M&A deals.

Mar 21, 2023

The company's orthopedic sales grew in the high single digits for 2022, and it launched new cornerstone products in high-growth segments.

Mar 14, 2023

With the exception of the pandemic-ridden 2020, OrthoPediatrics has grown in excess of 20% every year since its founding.

Mar 13, 2023

The company grew in the low single digits in 2022 as international growth in its orthopedics line offset competitive pressures in spine.

Mar 10, 2023

The company captured market share in 2022, growing more than 24% through new product introductions and expanded distribution.

Mar 10, 2023

The company declined in the mid-teens during 2022 as it exits markets, fills portfolio gaps and modernizes its operations.

Mar 03, 2023

The company grew 23% in 2022, its first year as a publicly traded company. New products and sales force expansion drove the growth.

Mar 03, 2023

The company grew more than 44% in 2022 through its sole focus on spine surgery. ATEC expects to grow another 25% in 2023.

Mar 02, 2023

The company's product revenue declined in the low single digits in 2022 as it transforms its business model and contends with supply issues.

Mar 02, 2023

The company grew 18% in 2022, driven by accelerating demand momentum in its core SI-fusion business and increased surgeon engagement.

Mar 01, 2023